IT1271624B - Derivati glucosidici di n-acil alchilamine capaci di esercitare effetto o neuroprotettivo utilizzabili nelle patologie acute e croniche del sistema nervoso centrale correlate ad eccitotossicita' - Google Patents

Derivati glucosidici di n-acil alchilamine capaci di esercitare effetto o neuroprotettivo utilizzabili nelle patologie acute e croniche del sistema nervoso centrale correlate ad eccitotossicita'

Info

Publication number
IT1271624B
IT1271624B ITMI940524A ITMI940524A IT1271624B IT 1271624 B IT1271624 B IT 1271624B IT MI940524 A ITMI940524 A IT MI940524A IT MI940524 A ITMI940524 A IT MI940524A IT 1271624 B IT1271624 B IT 1271624B
Authority
IT
Italy
Prior art keywords
acyl
acute
nervous system
central nervous
alchylamines
Prior art date
Application number
ITMI940524A
Other languages
English (en)
Inventor
Valle Francesco Della
Alberta Leon
Gabriele Marcolongo
Valle Federica Della
Original Assignee
Lifegroup Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifegroup Spa filed Critical Lifegroup Spa
Publication of ITMI940524A0 publication Critical patent/ITMI940524A0/it
Priority to ITMI940524A priority Critical patent/IT1271624B/it
Priority to AT95928857T priority patent/ATE169629T1/de
Priority to EP95928857A priority patent/EP0751947B1/en
Priority to ES95928857T priority patent/ES2124012T3/es
Priority to DE69504048T priority patent/DE69504048T2/de
Priority to PCT/EP1995/001026 priority patent/WO1995025736A1/en
Priority to AU21100/95A priority patent/AU2110095A/en
Priority to CA002186245A priority patent/CA2186245C/en
Priority to JP52438195A priority patent/JP4063864B2/ja
Priority to DK95928857T priority patent/DK0751947T3/da
Publication of ITMI940524A1 publication Critical patent/ITMI940524A1/it
Application granted granted Critical
Publication of IT1271624B publication Critical patent/IT1271624B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Si descrivono nuovi derivati glucosidici di N-acil alchilamine e il loro impiego nella cura di patologie acute e croniche del sistema nervoso centrale correlate a sovrastimolazione dei recettori agli amminoacidi eccitatori.
ITMI940524A 1994-03-21 1994-03-21 Derivati glucosidici di n-acil alchilamine capaci di esercitare effetto o neuroprotettivo utilizzabili nelle patologie acute e croniche del sistema nervoso centrale correlate ad eccitotossicita' IT1271624B (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ITMI940524A IT1271624B (it) 1994-03-21 1994-03-21 Derivati glucosidici di n-acil alchilamine capaci di esercitare effetto o neuroprotettivo utilizzabili nelle patologie acute e croniche del sistema nervoso centrale correlate ad eccitotossicita'
DE69504048T DE69504048T2 (de) 1994-03-21 1995-03-20 Glukosid-derivate von n-acyl-alkylaminen mit neuroprotektiver,neurotrophischer und entzündungshemmender wirkung für die behandlung von zentralnervensystemerkrankungen
EP95928857A EP0751947B1 (en) 1994-03-21 1995-03-20 Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity
ES95928857T ES2124012T3 (es) 1994-03-21 1995-03-20 Derivados glucosidicos de n-acilalquilaminas que ejercen accion neuroprotectora y neurotrofica utiles en trastornos agudos y cronicos del sistema nervioso central relacionados con excitotoxicidad.
AT95928857T ATE169629T1 (de) 1994-03-21 1995-03-20 Glukosid-derivate von n-acyl-alkylaminen mit neuroprotektiver,neurotrophischer und entzündungshemmender wirkung für die behandlung von zentralnervensystemerkrankungen
PCT/EP1995/001026 WO1995025736A1 (en) 1994-03-21 1995-03-20 Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity
AU21100/95A AU2110095A (en) 1994-03-21 1995-03-20 Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity
CA002186245A CA2186245C (en) 1994-03-21 1995-03-20 Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity
JP52438195A JP4063864B2 (ja) 1994-03-21 1995-03-20 興奮性毒性に関連した中枢神経系の急性ならびに慢性障害に有用な、神経保護、神経栄養、ならびに抗炎症作用を有するｎ−アシルアルキルアミンのグルコシド誘導体
DK95928857T DK0751947T3 (da) 1994-03-21 1995-03-20 Glucosidderivater af N-acylalkylaminer, der udøver neurobeskyttende, neurotrop og anti-inflammatorisk virkning, og som er a

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI940524A IT1271624B (it) 1994-03-21 1994-03-21 Derivati glucosidici di n-acil alchilamine capaci di esercitare effetto o neuroprotettivo utilizzabili nelle patologie acute e croniche del sistema nervoso centrale correlate ad eccitotossicita'

Publications (3)

Publication Number Publication Date
ITMI940524A0 ITMI940524A0 (it) 1994-03-21
ITMI940524A1 ITMI940524A1 (it) 1995-09-21
IT1271624B true IT1271624B (it) 1997-06-04

Family

ID=11368282

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI940524A IT1271624B (it) 1994-03-21 1994-03-21 Derivati glucosidici di n-acil alchilamine capaci di esercitare effetto o neuroprotettivo utilizzabili nelle patologie acute e croniche del sistema nervoso centrale correlate ad eccitotossicita'

Country Status (9)

Country Link
EP (1) EP0751947B1 (it)
JP (1) JP4063864B2 (it)
AT (1) ATE169629T1 (it)
AU (1) AU2110095A (it)
DE (1) DE69504048T2 (it)
DK (1) DK0751947T3 (it)
ES (1) ES2124012T3 (it)
IT (1) IT1271624B (it)
WO (1) WO1995025736A1 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4070966B2 (ja) * 2001-06-28 2008-04-02 株式会社カネボウ化粧品 新規ガラクトシルセラミド類縁体及び用途
DE602006013787D1 (de) * 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
KR101116868B1 (ko) * 2008-10-20 2012-02-29 성균관대학교산학협력단 안질환의 예방 또는 치료용 조성물
CN105102466B (zh) * 2012-11-28 2018-07-27 维多利亚林克有限公司 作为bace-1的抑制剂的糖树枝状簇化合物
JP6445453B2 (ja) * 2012-11-28 2018-12-26 ビクトリア リンク リミテッド 樹状コア化合物
CN105418698B (zh) * 2015-12-21 2018-04-27 上海市第七人民医院 一种酰胺乙氧基-β-D-葡萄糖苷类化合物及其制备方法和应用
CN110612305B (zh) * 2017-03-23 2023-11-28 维多利亚林克有限公司 硫酸乙酰肝素糖模拟化合物及其医药与化妆品用途
US12611419B2 (en) 2017-12-21 2026-04-28 Innomedica Holding Ag Liposomal composition for use in a method of treating Parkinson's disease
CN115466178B (zh) * 2021-06-11 2024-06-11 青岛海合生物科技有限公司 一种神经酸衍生物及其制备方法和应用
FR3147951A1 (fr) * 2023-04-19 2024-10-25 Paris Sciences Et Lettres Particules de monosaccharides modifies par une chaine hydrophobe et de cyclodextrine.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1260156B (it) * 1992-08-03 1996-03-28 Fidia Spa Derivati dell'acido neuraminico

Also Published As

Publication number Publication date
AU2110095A (en) 1995-10-09
WO1995025736A1 (en) 1995-09-28
DK0751947T3 (da) 1999-05-10
ITMI940524A0 (it) 1994-03-21
DE69504048T2 (de) 1999-04-22
ITMI940524A1 (it) 1995-09-21
ATE169629T1 (de) 1998-08-15
EP0751947A1 (en) 1997-01-08
ES2124012T3 (es) 1999-01-16
JPH09510469A (ja) 1997-10-21
DE69504048D1 (de) 1998-09-17
JP4063864B2 (ja) 2008-03-19
EP0751947B1 (en) 1998-08-12

Similar Documents

Publication Publication Date Title
ID28003A (id) Turunan-turunan adamantana
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
BR9712808A (pt) Indol-3-glioxilamidas n-substituìdas com efeito antiasmático, anti-alérgico e imunossupressor/imunomodulador
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HU9601161D0 (en) Use of retinoids in cosmetic compositions or for the manufacture of pharmaceutical compositions
IT1271624B (it) Derivati glucosidici di n-acil alchilamine capaci di esercitare effetto o neuroprotettivo utilizzabili nelle patologie acute e croniche del sistema nervoso centrale correlate ad eccitotossicita'
GR3036675T3 (en) Piperazino derivatives as neurokinin antagonists
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
PT942741E (pt) Composicoes de lectina e suas utilizacoes
FR2755965B1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
WO1996032403A3 (de) Neue cytosin- und cytidinderivate
ITRM910730A0 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" diradicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
NZ294878A (en) Water soluble derivatives of epipodophyllotoxin and medicaments
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
AU6736096A (en) 1(hetero)aryl-4-(condensed thiazol-2-ylalkyl)-piperazine derivatives, their preparation and their use in the treatment of 5-ht1a-receptor mediated disorders
ITTO910610A1 (it) Polpa d'amido, procedimento per la sua preparazione e suo impiego nella fabbricazione di carta e cartone.
ES2188140T3 (es) Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento.
DE69323191D1 (de) Wasserlösliche retinoide
ES2147576T3 (es) Utilizacion del efaroxan y de sus derivados para la preparacion de un medicamento destinado al tratamiento de la enfermedad de parkinson.
AU5811196A (en) New quinoxalinedione derivatives, their production and use in pharmaceutical agents

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970227